BF Biosciences Limited (PSX:BFBIO)
Pakistan
· Delayed Price · Currency is PKR 152.32
-0.08 (-0.05%)
At close: Dec 5, 2025
BF Biosciences Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2019 |
| Revenue | 6,883 | 5,837 | 3,659 | 1,810 | 1,521 | 1,755 | Upgrade
|
| Revenue Growth (YoY) | 68.70% | 59.55% | 102.19% | 18.99% | -13.34% | 179.30% | Upgrade
|
| Cost of Revenue | 4,124 | 3,553 | 2,128 | 1,362 | 1,063 | 958.33 | Upgrade
|
| Gross Profit | 2,759 | 2,285 | 1,531 | 447.24 | 457.77 | 796.47 | Upgrade
|
| Selling, General & Admin | 1,935 | 1,503 | 755.61 | 158.5 | 187.12 | 152.55 | Upgrade
|
| Other Operating Expenses | 12.3 | 47.22 | 64.01 | 19.46 | 28.42 | 42.73 | Upgrade
|
| Operating Expenses | 1,947 | 1,550 | 819.62 | 177.96 | 215.54 | 195.29 | Upgrade
|
| Operating Income | 811.73 | 734.56 | 711.15 | 269.29 | 242.23 | 601.18 | Upgrade
|
| Interest Expense | -106.74 | -115.38 | -141.24 | -1.22 | -65.62 | -25.27 | Upgrade
|
| Interest & Investment Income | 95.02 | 95.02 | 19.34 | 83.4 | 141 | 39 | Upgrade
|
| Currency Exchange Gain (Loss) | -9.08 | -9.08 | -0.11 | -8.18 | 28.15 | 28.7 | Upgrade
|
| Other Non Operating Income (Expenses) | -11.47 | -11.47 | -9.6 | -151.08 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 779.45 | 693.64 | 579.54 | 192.21 | 345.76 | 643.61 | Upgrade
|
| Gain (Loss) on Sale of Investments | 27.3 | 27.3 | 0.21 | 8.93 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.79 | 2.79 | 2.13 | 1.06 | 3 | 2 | Upgrade
|
| Pretax Income | 809.55 | 723.74 | 581.88 | 202.2 | 348.76 | 645.61 | Upgrade
|
| Income Tax Expense | 318.15 | 276.59 | 196.47 | 53.14 | 41.78 | 37.62 | Upgrade
|
| Net Income | 491.4 | 447.15 | 385.41 | 149.05 | 306.98 | 607.99 | Upgrade
|
| Net Income to Common | 491.4 | 447.15 | 385.41 | 149.05 | 306.98 | 607.99 | Upgrade
|
| Net Income Growth | 22.88% | 16.02% | 158.57% | -51.44% | -49.51% | 1190.62% | Upgrade
|
| Shares Outstanding (Basic) | 87 | 81 | 63 | 63 | 63 | 63 | Upgrade
|
| Shares Outstanding (Diluted) | 87 | 81 | 63 | 63 | 63 | 63 | Upgrade
|
| Shares Change (YoY) | 37.69% | 27.79% | - | 0.01% | - | - | Upgrade
|
| EPS (Basic) | 5.64 | 5.52 | 6.09 | 2.35 | 4.85 | 9.60 | Upgrade
|
| EPS (Diluted) | 5.64 | 5.52 | 6.09 | 2.35 | 4.85 | 9.60 | Upgrade
|
| EPS Growth | -10.76% | -9.21% | 158.57% | -51.45% | -49.51% | 1190.62% | Upgrade
|
| Free Cash Flow | -5.44 | -29.71 | 521.57 | -2,164 | -952 | -371 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.37 | 8.23 | -34.17 | -15.03 | -5.86 | Upgrade
|
| Gross Margin | 40.08% | 39.13% | 41.84% | 24.72% | 30.10% | 45.39% | Upgrade
|
| Operating Margin | 11.79% | 12.58% | 19.44% | 14.88% | 15.93% | 34.26% | Upgrade
|
| Profit Margin | 7.14% | 7.66% | 10.53% | 8.24% | 20.19% | 34.65% | Upgrade
|
| Free Cash Flow Margin | -0.08% | -0.51% | 14.26% | -119.61% | -62.60% | -21.14% | Upgrade
|
| EBITDA | 1,055 | 926.49 | 746.72 | 303.06 | 270.23 | 624.18 | Upgrade
|
| EBITDA Margin | 15.33% | 15.87% | 20.41% | 16.75% | 17.77% | 35.57% | Upgrade
|
| D&A For EBITDA | 243.56 | 191.92 | 35.57 | 33.78 | 28 | 23 | Upgrade
|
| EBIT | 811.73 | 734.56 | 711.15 | 269.29 | 242.23 | 601.18 | Upgrade
|
| EBIT Margin | 11.79% | 12.58% | 19.44% | 14.88% | 15.93% | 34.26% | Upgrade
|
| Effective Tax Rate | 39.30% | 38.22% | 33.76% | 26.28% | 11.98% | 5.83% | Upgrade
|
| Advertising Expenses | - | 239.6 | 149.49 | 32.03 | 17 | 16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.